Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.
Campbell Discusses Choices for Patients With Favorable- and Intermediate-Risk RCC
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.
Read More
Roundtable Discussion: Voss Looks at Integrating New Approaches in Clear Cell RCC Treatment
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.
Read More
Recent Advances in the Management of Advanced Renal Cell Carcinoma (RCC)
February 24th 2023In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.
Read More
2 Clarke Drive
Cranbury, NJ 08512